News | Breast Density | May 09, 2016

Gamma Medica Launches Dense Breast Tissue Education Campaign

Campaign centered on microsite featuring information, statistics and testimonials on risks of dense breast tissue, benefits of molecular breast imaging

Gamma Medica, Be Certain education campaign, breast density, microsite, molecular breast imaging

May 9, 2016 — Gamma Medica, provider of molecular breast imaging technology (MBI), announced it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density.

Today, about half of all women in the United States have dense breast tissue, making them four to five times more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime.

The goal of the campaign is to confront the 40,000 deaths annually at the hands of breast cancer by empowering women to be proactive about their breast health and consult their doctors to gain a better understanding of risks associated with dense breast tissue. The microsite provides patients with a one-stop educational resource with the most updated, accurate information for women with dense breast tissue, allowing them to Be Certain about their screening results and the latest clinical data on breast cancer.

With the Be Certain campaign, Gamma Medica aims to shift the public conversation on breast cancer awareness by educating patients, physicians, breast surgeons, radiologists and the industry about how MBI can increase detection rates by 400 percent and offer other benefits when used as a supplemental screening tool to the traditional mammogram. Visitors will have access to accurate information and statistics, testimonials and patient stories.

For more information:

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages